NasdaqGS:MRNA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Moderna's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MRNA's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

17.7%

MRNA

1.9%

US Biotechs

2.1%

US Market


1 Year Return

436.0%

MRNA

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: MRNA exceeded the US Biotechs industry which returned 21.1% over the past year.

Return vs Market: MRNA exceeded the US Market which returned 19.7% over the past year.


Shareholder returns

MRNAIndustryMarket
7 Day17.7%1.9%2.1%
30 Day54.5%6.5%8.1%
90 Day61.8%7.1%6.0%
1 Year436.0%436.0%23.3%21.2%22.5%19.8%
3 Yearn/a21.7%15.4%46.5%36.8%
5 Yearn/a14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Moderna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moderna undervalued compared to its fair value and its price relative to the market?

15.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MRNA ($109.18) is trading above our estimate of fair value ($16.72)

Significantly Below Fair Value: MRNA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MRNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MRNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRNA is overvalued based on its PB Ratio (15.6x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Moderna forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

1.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: MRNA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MRNA's is expected to become profitable in the next 3 years.

Revenue vs Market: MRNA's revenue (30.2% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: MRNA's revenue (30.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRNA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Moderna performed over the past 5 years?

-26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRNA is currently unprofitable.

Growing Profit Margin: MRNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MRNA is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare MRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: MRNA has a negative Return on Equity (-21.66%), as it is currently unprofitable.


Next Steps

Financial Health

How is Moderna's financial position?


Financial Position Analysis

Short Term Liabilities: MRNA's short term assets ($3.6B) exceed its short term liabilities ($1.5B).

Long Term Liabilities: MRNA's short term assets ($3.6B) exceed its long term liabilities ($417.5M).


Debt to Equity History and Analysis

Debt Level: MRNA is debt free.

Reducing Debt: MRNA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MRNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MRNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.6% per year.


Next Steps

Dividend

What is Moderna current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Stéphane Bancel (47 yo)

9.08yrs

Tenure

US$8,948,207

Compensation

Mr. Stéphane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering and a Trustee of...


CEO Compensation Analysis

Compensation vs Market: Stéphane's total compensation ($USD8.95M) is about average for companies of similar size in the US market ($USD10.79M).

Compensation vs Earnings: Stéphane's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Noubar Afeyan
Co-Founder8.75yrsUS$530.00k0.53%
$ 229.5m
Stéphane Bancel
CEO & Director9.08yrsUS$8.95m4.03%
$ 1.7b
Stephen Hoge
Presidentno dataUS$5.00m0.48%
$ 207.5m
Tal Zaks
Chief Medical Officer5.67yrsUS$4.83mno data
Juan Andres
Chief Technical Operations & Quality Officer3.25yrsUS$3.86mno data
David Meline
CFO & Principal Accounting Officer0.42yrno data0.00038%
$ 164.2k
John V. Reynders
Chief Information Officer7.33yrsno datano data
Melissa Moore
Chief Scientific Officer & Member of Scientific Advisory Boardno datano datano data
Lavina Talukdar
Head of Investor Relations1.58yrsno datano data
Lori Henderson
General Counsel & Corporate Secretary2.58yrsno data0.00017%
$ 73.4k
Colleen Hussey
Senior Manager of Corporate Communicationsno datano datano data
Tracey Franklin
Chief Human Resources Officer1.08yrsno datano data

3.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MRNA's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Noubar Afeyan
Co-Founder8.75yrsUS$530.00k0.53%
$ 229.5m
Stéphane Bancel
CEO & Director9.08yrsUS$8.95m4.03%
$ 1.7b
Melissa Moore
Chief Scientific Officer & Member of Scientific Advisory Boardno datano datano data
Paul Sagan
Independent Non Executive Director2.42yrsUS$492.50k0.11%
$ 45.9m
Robert Langer
Independent Non Executive Director & Member of Scientific Advisory Board9.92yrsUS$500.00k2.91%
$ 1.3b
Scott Canute
Member of Technology Advisory Board6.5yrsno datano data
Fred Regnier
Member of Technology Advisory Board6.5yrsno datano data
James Swartz
Member of Technology Advisory Board6.5yrsno datano data
Ulrich von Andrian-Werburg
Member of Scientific Advisory Boardno datano datano data
Jack Szostak
Chairman of Scientific Advisory Boardno datano datano data
John Aunins
Member of Technology Advisory Board6.5yrsno datano data
Stephen Berenson
Independent Non Executive Director3.08yrsUS$500.00k0.0058%
$ 2.5m

6.5yrs

Average Tenure

59yo

Average Age

Experienced Board: MRNA's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Top Shareholders

Company Information

Moderna, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moderna, Inc.
  • Ticker: MRNA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$43.204b
  • Shares outstanding: 395.71m
  • Website: https://www.modernatx.com

Number of Employees


Location

  • Moderna, Inc.
  • 200 Technology Square
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2018
0QFMUN (Boerse Muenchen)YesCommon StockDEEURDec 2018
0QFDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2018
MRNA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNDec 2018
MRNABVL (Bolsa de Valores de Lima)YesCommon StockPEUSDDec 2018
0A45LSE (London Stock Exchange)YesCommon StockGBUSDDec 2018
M1RN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 10 REPR 1 COM NPVBRBRLOct 2020

Biography

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:54
End of Day Share Price2020/11/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.